Why the study?
Does laparoscopic adjustable gastric banding (LAGB) reduce obesity-related peptides in morbidly obese patients?
Does laparoscopic adjustable gastric banding (LAGB) reduce obesity-related peptides in morbidly obese patients?
Laparoscopic adjustable gastric banding leads to significant weight loss and a reduction in obesity-related peptides at 6 months, improving the metabolic risk profile in morbidly obese patients.
LAGB was associated with reduced obesity peptides; leaves open whether this improves outcomes, needing RCTs.
BACKGROUND: The aim of this study was to examine the relationship between weight loss and resistin, apelin, chemerin, and visfatin after laparoscopic adjustable gastric banding (LAGB). METHODS: ) subjects formed the control group. We obtained blood samples from the study subjects at three different times: before undergoing surgery and at one month and 6 months after surgery. Blood was obtained once from the control group. RESULTS: Significant weight loss was achieved at one and 6 months after surgery. Plasma levels of apelin, resistin, chemerin, and visfatin were higher in morbidly obese patients compared with the control group. Obesity-related peptides decreased one month and 6 months after surgery. CONCLUSIONS: Elevated plasma resistin, apelin, chemerin, and visfatin levels in morbidly obese patients are gradually reduced after weight loss. According to these findings, LAGB surgery is found to be an important and efficient means for morbidly obese patients both to lose weight and to develop a better metabolic risk profile in a short time period.
No takes yet. Share an insight, caveat, or question.
Arica et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: